2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2429

Zipcode-Binding Protein 1 (ZBP1) Facilitates Ro60 Surface Translocation, Cellular Growth and Autoimmune Sequelae
Abstract Number: 2430

Detection and Clinical Significance of Circulating M3 Muscarinic Acetylcholine Receptor Reactive Th17 Cells in Patients with Primary Sjögren’s Syndrome
Abstract Number: 2431

Extracellular Vesicles in Primary Sjögren’s Syndrome: A Promising Source for Novel Proteomic Biomarkers
Abstract Number: 2432

Thymic Stromal Lymphopoietin (TSLP) as a Biomarker of Primary Sjögren’s Syndrome (pSS) and Related Lymphoma: Results in Independent Cohorts
Abstract Number: 2433

Fatigue in Primary Sjögren’s Syndrome as a Manifestation of Heavier Disease Activity of Mucosa-Associated Lymphoid Tissue (MALT)
Abstract Number: 2434

Risk of Lymphoma and Thyroid Cancer in Primary Sjögren’s Syndrome Measured Using the Korean Health Insurance Claims Database
Abstract Number: 2435

Data Driven Prediction Lymphoma Model and 10-year Overall Survival Rates of a Large Harmonized Cohort of Patients with Primary Sjögren’s Syndrome Associated Lymphomas
Abstract Number: 2436

The Salivary Glands as the Key Site of Inflammation and Lymphoproliferation Leading to Lymphoma in Primary Sjögren’s Syndrome: Relevance for Dedicated Scoring, Biomarker Development and Lymphoma Prevention
Abstract Number: 2437

Autoantibodies from Sjögren’s Syndrome Enhance NLRP3 Inflammasome Activation and IL-18 Production in Human Salivary Gland Cell Line A-253
Abstract Number: 2438

Autoantibody Mediated Salivary Gland Hypofunction in Sjögren’s Syndrome Involves Activation of Innate Immunity and Endothelial Cells
Abstract Number: 2439

Cardiovascular Impact of Hyperuricemia in Patients with Psoriatic Arthritis
Abstract Number: 2440

Bone Mineral Density in Psoriatic Arthritis: Results from a Longitudinal Study
Abstract Number: 2441

Rates of Treated Depression Among Patients with Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs, and Corticosteroids in the US MarketScan Database
Abstract Number: 2442

The Relationship Between Fatigue and Disease Activity as Determined by Different Indices in Patients with Psoriatic Arthritis (PsA)
Abstract Number: 2443

A Gender-based Analysis of Disease Activity and Its Relationship with Anxiety, Depression, Fatigue, and Fibromyalgia in Psoriatic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].